Common Mozyme Side Effects

The most commonly reported Mozyme side effects (click to view or check a box to report):

Sepsis (1)
Respiratory Failure (1)
No Therapeutic Response (1)

If you or someone in your family has experienced a serious side effect to a health product, you are encouraged to report the experience to your health care professional (e.g. physician, pharmacist). You could also complete a copy of the side effect reporting form or report your side effect to FDA.

Mozyme Side Effects Reported to FDA

Mozyme Side Effect Report#6073378-3
No Therapeutic Response, Respiratory Failure, Sepsis
This is a report of a male patient (weight: NA) from United Kingdom, suffering from the following health symptoms/conditions: glycogen storage disease type ii, who was treated with Mozyme (alglucosidase Alfa) Powder For Solution For Infusion (dosage: 20 Mg/kg, Q2w, Intravenous, start time:
Sep 23, 2008), combined with: NA. and developed a serious reaction and side effect(s): No Therapeutic Response, Respiratory Failure, Sepsis after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Mozyme (alglucosidase Alfa) Powder For Solution For Infusion treatment in male patients, resulting in No Therapeutic Response side effect.

The appearance of Mozyme on this list does not mean that FDA has concluded that the drug has the listed risk. It means that FDA has identified a potential safety issue, but it does not mean that FDA has found a causal relationship between the drug and the listed risk.

What are common Mozyme Side Effects for Women?

Women Side Effects Reports

What are common Mozyme Side Effects for Men?

Men Side Effects Reports
No Therapeutic Response 1
Respiratory Failure 1
Sepsis 1

Track Your Side Effects

Note Your Observations

It is really important to keep track of your health symptoms, right from the time you start a new medicine. You can do it any way you prefer: in a notebook, in a computer file or using our online tool. You should also note down any other medicines you are taking at the same time, because there could be an interaction between these medicines.

Why Your Notes are Important

Your notes could be helpful in several ways:

  • You can use them to remind you of details that may alert your health care professional(s) to a problem
  • You will have a record to refer to in the future, in case you are ever prescribed the same medicine again

  • Log Form

    You can use the following log form to write down important information, like the date and time you experienced a side effect and your symptoms, how strong the symptoms were, and any other medicines you were using.

    Medicine Name and Dosage:
    Side Effects Scale Date & Time Other Medicine(s) or Treatment(s)
    Scale: 1 = very mild to 10 = very bad

    Side effects reports are analyzed to discover potential health product safety signals. Some important reactions may take an extremely long time to develop or occur infrequently. Continued monitoring of adverse reactions is thus essential to maintain a comprehensive safety and effectiveness profile of health products.

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

    Mozyme reports list potential signals of serious risks and new safety information that were identified using the FDA Adverse Event Reporting System (FAERS).
    FAERS is a database that contains information on adverse event and medication errors reports submitted to FDA by healthcare professionals (such as physicians, pharmacists, nurses and others), consumers (such as patients, family members, layers and others) and manufacturers.

    Discuss Mozyme Side Effects

    Did You Have a Mozyme Side Effect?

    Yes, Severe
    Yes, Moderate
    Yes, Minor

    How Effective is Mozyme for You?

    Exceeded Expectations
    Somewhat Effective
    Not Effective

    Mozyme Safety Alerts, Active Ingredients, Usage Information

    NDC 50242-100
    Proprietary Name Pulmozyme
    Name dornase alfa
    Dosage Form SOLUTION
    On market since 19931230
    Labeler Genentech, Inc.
    Active Ingredient(s) DORNASE ALFA
    Strength(s) 1
    Unit(s) mg/mL
    Pharma Class Decreased Respiratory Secretion Viscosity [PE],Deoxyribonuclease I [Chemical/Ingredient],Recombinant

    More About Mozyme

    Side Effects reported to FDA: 1

    Mozyme safety alerts: 2000

    Pulmozyme (dornase alfa, recombinant) Oct 2000

    Genentech, Inc. is voluntarily recalling one lot of Pulmozyme because an unapproved re-filtration step was utilized to remove metal particulates that had been found in the concentrated bulk drum substance.

    [October 12, 2000 - Notice - FDA]

    Latest Mozyme clinical trials

    Mozyme Reviews

    No reviews, be a first to report a side effect via side effect reporting form

    privacy policy